Abstract: The invention is directed to methods of treating ischemic stroke by adminis-tering a therapeutically effective amount of at least one compound of Formula I or Formula II to a subject in need thereof, wherein the compound has Formula I or Formula II: or a salt or ester of (I) or (II); wherein X is OH, C1-C6 alkoxyl, 18F, or 19F; Y and Z are independently selected from C1-C6 alkyl, C1-C6 alkoxyl, halogen, substituted or unsubstituted C1-C6 amine, 18F, 19F, or H; and n is 1, 2, or 3.

Abstract: The present disclosure provides a drug for preventing and treating alopecia and belongs to the technical field of pharmaceutical products. The drug for preventing and treating alopecia comprises the following active ingredients: a composition including more than one of flavonoid compound with effects of decreasing capillary permeability, calcium and vitamin C. The composition in the present disclosure can be adopted to achieve aims of effectively preventing and treating alopecia and promoting hair growth, and is safe in property, wide in universality, obvious in curative effects and suitable for treatment of androgenetic alopecia.

Abstract: A cannabis-based therapeutic product for treatment of sleep disorders produced (a) harvesting flowers and leaves from a plurality of cannabis plants from a plurality of cannabis strains each expressing a different active cannabis compound profile; (b) individually extracting cannabis oil from the harvested flowers and leaves of each of the cannabis strains; (c) concentrating the extracted cannabis oils by at least evaporating extraneous material; and (d) combining specific amounts of the concentrated oils from one or more cannabis strains to produce a mixture possessing a specific active cannabis compound profile.

Abstract: Disclosed herein are compositions and methods to increase glucose uptake and fat metabolism. The disclosed composition can comprise a PI3K agonist; a TRPM8 agonist; and a pharmaceutically, nutraceutically, or cosmetically acceptable carrier. Also disclosed is a method of treating diabetes, obesity, or metabolic syndrome in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a PI3K agonist and a TRPM8 agonist. Also disclosed is a method of treating a skin condition in a subject, comprising topically administering to a subject in need thereof an effective amount of a composition comprising a PI3K agonist and a TRPM8 agonist.

Abstract: The present invention relates to cannabinoid compositions. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.

Abstract: The invention is composition and methods that restore balance to the stress-related steroidal hormone cascade. Upon co-administration, the compounds of the invention restore balance to the cascade and promote or restore normal function in patients suffering from a disorder having a primary psychological stress component. The compositions include a selected combination of isoflavones, alpha lipoic acid, and L dopamine or a precursor thereof, and are preferably obtained from the natural sources disclosed herein. The uses of the invention include administration of the disclosed compositions to patients suffering from PTSD, fibromyalgia, endometriosis, and other disorders having a common chronic stress component.

Abstract: A dosage delivery film composition containing a botanical drug substance formable into a bioerodible dosage delivery film, the dosage delivery film composition including: (i) one or more of: a polymer, a plasticizer, a defoamer, or an antioxidant; (ii) a cannabinoid-cyclodextrin-terpene complex or a cannabinoid-terpene-surfactant micelle, and (iii) optionally, one or more of: a taste mask, a vasodilator, or a lipophilic vehicle to transport the botanical drug substance across the mucous membrane.

Abstract: This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containing the complex, and their uses in the manufacture of a medicament for treating diabetes and/or diabetes-related diseases.

Abstract: Methods of treatment and pharmaceutical formulation configured to improve the cure rate of patients with solid tumors when treated with radiotherapy are provided. The methods and treatments use an inhibitor of the CXCL12/CXCR4 pathway. The inhibitors prevent the formation of new blood vessels into a tumor that is being treated with radiotherapy. The inhibitor may be continuously infused intravenously towards the end of radiotherapy and continuing thereafter.

Abstract: Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as CpdA. The methods and compositions may be used for treating diseases, disorders, and conditions associated with glucocorticoid receptor activity, androgen receptor activity, or both, such as cancers, acne vulgaris, and alopecia.

Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.

Abstract: The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.

Abstract: Methods for treating immunodeficiencies are provided using indole-based compounds.

Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.

Abstract: The object of the present invention is the synergistic combination of pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts thereof and hyaluronic acid and/or pharmaceutically acceptable salts thereof, for use in the treatment and/or prevention of dryness and irritation of the mucosae. A further object of the present invention are pharmaceutical compositions comprising the synergistic combination of pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts thereof and hyaluronic acid and/or pharmaceutically acceptable salts thereof, and at least one physiologically acceptable excipient, and the use of such compositions in the treatment and/or prevention of dryness and irritation of the mucosae.

Abstract: The present invention relates to various topical veterinary compositions comprising fipronil, an insect growth regulator, and a veterinarily acceptable carrier.

Abstract: The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.

Abstract: A novel combination comprising an androgen receptor inhibitor, for example: 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide or a pharmaceutically acceptable salt thereof, and an AKT inhibiting compound, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and/or AKT inhibition is beneficial, e.g., cancer.

Abstract: A problem to be solved by the present invention is to provide a method for ameliorating pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria by finding a composition that enhances the antidiuretic action of vasopressin or a vasopressin V2 receptor agonist. As a result of the studies, it has been found that imidafenacin enhances the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, whereby the present invention has been completed. According to the present invention, a composition containing imidafenacin can enhance the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, making it possible to ameliorate pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria.

Abstract: The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

Abstract: The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.

Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.

Abstract: The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.

Abstract: Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.

Abstract: Methods are provided for the targeted treatment of Epidermolysis Bullosa simplex.

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of tinnitus.

Abstract: The present invention provides for a drug delivery system for anti-cancer compound and method of preparation thereof.

Abstract: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

Abstract: Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing ?-galactosidase A activity in the patient.

Abstract: Methods for treatment of fibrotic diseases using compounds of formula I wherein RA is hydrogen, R7 and R8 are independently selected from H and SO2NR3R4, one of R7 and R8 is hydrogen, and R1, R2, R3, and R4 are each independently selected from H, alkyl, heteroalkyl, cycloalkyl, arylcycloalkyl, aryl, heteroaryl, heterocycloalkyl, and each of NR1R2 and NR3R4 can independently combine to form a heterocycloalkyl, and wherein said alkyl, heteroalkyl, cycloalkyl, arylcycloalkyl, aryl, heteroaryl, or heterocycloalkyl may be optionally substituted, or a pharmaceutically acceptable salt, ester, amide, stereoisomer, geometric isomer or prodrug thereof.

Abstract: The present application relates to topical formulations in the form of an oil-in-water emulsion comprising nifedipine and a photostabilizing effective amount of quercetin or a photostabilizing effective amount of a combination of quercetin and butyl methoxydibenzoylmethane (BMDBM). Such topical formulations may, for example, be used for the treatment of diseases, disorders or conditions that benefit from topical administration of nifedipine such as but not limited to Raynaud phenomenon, chilblains or wound healing.

Abstract: In the invention provides a WNT/?-catenin signal transduction inhibitor selected from (i) axitinib, (ii) pazopanib, (iii) orlistat, (iv) topotecan, (v) pharmaceutically effective substitution derivatives thereof, or (vi) pharmaceutically acceptable salts, or solvates or hydrates thereof, diastereoisomers, tautomers, enantiomers, and prodrugs and active metabolites thereof, for use in the treatment or prevention of a disease or condition in which WNT/?-catenin signal transduction is a contributing factor and for use in a method for the immunotherapy of a hyperproliferative or neoplastic disease or condition in a subject in which DCs are administered to the subject. The invention further provides an in vitromethod for diagnosing WNT/?-catenin dependent cancers, said method comprising (i) contacting a sample of cells from a test cancer with one or more of the WNT/?-catenin signal transduction inhibitors disclosed herein, and (ii) assessing the effects of said inhibitor on said sample.

Abstract: The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.

Abstract: The present disclosure relates to tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less, methods of producing the same, as well as compositions related thereto. The disclosure further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO.

Abstract: Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of cinitapride or derivative thereof. The compositions include an effective amount of cinitapride or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.

Abstract: The invention relates to the use of a pharmaceutical composition containing nicotinamide (NAM) and/or pyruvate as a neuroprotective medicament or gene therapy in the treatment of neurodegenerative disorders, in particular axon degeneration of neuronal tissue in ocular-related neurodegeneration diseases including glaucoma.

Abstract: Embodiments relate to compositions comprising a prochlorperazine compound and a nasal carrier, including methods for formulating such compositions for pharmaceutical applications, for example, for treating or reducing the incidence of migraine headaches. Additional embodiments relate to articles comprising a prochlorperazine compound and a nasal carrier, including use of such articles as nasal drops or nasal sprays. Further embodiments relate to methods for using such articles, for example, for treating or reducing the incidence of migraines.

Abstract: The methods disclosed herein relate to the treatment of chronic inflammatory dermal disorder in humans, by administering a therapeutically effective amount of RS-norketotifen.

Abstract: The present invention is effective for the treatment and relief of cough produced by posterior nasal secretion, through the use of the combination of Oximetazoline and Ipratropium. The active agents enunciated in the combination of the present invention have been used and marketed separately with different uses to those of the present invention. The oxymetazoline to eliminate nasal secretion and congestion (obstruction), and ipratropium bromide is marketed for the purpose of dilating the bronchial tubes in asthmatic patients with chronic obstructive pulmonary disease, although experimentally it has also been used to decrease nasal secretion. Both active agents, together or separately have not been used so far as antitussives intranasally. The cough produced by the posterior nasal secretion, is the most frequent cause of cough in the human being of any age, the present invention is effective for the treatment and relief of said symptom.

Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: The present disclosure relates to novel compounds, compositions comprising these compounds, and their use, for example for the treatment of cancer. In particular, the present disclosure includes compounds of Formula (I), and compositions and uses thereof.

Abstract: The present invention provides a transdermal delivery device comprising a pharmaceutical composition, wherein said composition comprises a N-oxide derivative of an opioid antagonist, or a salt thereof, and an opioid agonist or salt thereof.

Abstract: Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.

Abstract: Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

Abstract: Provided herein are triazole compounds and pharmaceutical compositions comprising said compounds useful as modulators of DAGL(?) and DAGL(?). In some embodiments, the compounds described herein are selective DAGL(?) inhibitors. Furthermore, the subject compounds and compositions are useful for the treatment of neurodegenerative or neuroinflammatory disease.

Abstract: The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof.

Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.